AbbVie's etentamig cuts progression-or-death risk 60% in Phase 3 CERVINO myeloma trial

AbbVie says its BCMA×CD3 bispecific etentamig (ABBV-383) lowered the risk of disease progression or death by 60% against standard therapies in the Phase 3 CERVINO trial in relapsed/refractory multiple myeloma — a monotherapy result the company reports as meeting both primary endpoints, overall response rate and progression-free survival ^[1][2][3].

What AbbVie reported

The headline is a 60% reduction in the risk of progression or death versus standard therapies ^[1]. This is AbbVie's claim as carried by Endpoints News ^[1] and a syndicated AbbVie release ^[2]; the company reports that both primary endpoints — response rate and progression-free survival — were met ^[2][3]. No AbbVie press release or SEC 8-K disclosing CERVINO appears in the sources reviewed, and the exact response rate, the PFS hazard ratio, and the p-values are not disclosed. ChEMBL carries etentamig at maximum clinical phase 3.0, consistent with a Phase 3 readout ^[10].

The trial identity carries a caveat worth stating once, up front. Prognyx maps CERVINO to NCT06158841 — etentamig given intravenously as monotherapy against standard available therapy, roughly 421 patients, now active but no longer recruiting, with a registered primary completion of December 2027 — on matching design ^[4]. AbbVie has not linked the CERVINO name to that NCT in the sources reviewed, so the mapping is Prognyx's inference, not a stated fact. The topline therefore lands more than a year before that registered primary completion date; Prognyx read: this reads as a topline or interim analysis rather than final data.

Etentamig sits inside a multi-trial program running from Phase 1 through Phase 3, spanning monotherapy and immunomodulator combinations ^[4][6][7][8].

Why it matters

AbbVie's oncology portfolio was essentially flat going into this: $1.650B in net revenues in Q2 2026, down 1.5% year over year, with no mention of the readout in that July 31, 2026 filing because the win postdates it ^[11]. Prognyx read: a positive Phase 3 in relapsed/refractory myeloma hands AbbVie a growth asset in a BCMA class it did not previously carry commercially.

One conflation to avoid: AbbVie closed its roughly $10.9B acquisition of Apogee Therapeutics ($135.11 per share) on September 3, 2026 ^[12]. That is an immunology deal, not oncology, and has nothing to do with etentamig; reading the two as one story misreads the week.

Who is exposed — by name

Direct mechanistic peer. Pfizer's elranatamab is described in the peer-reviewed literature as a BCMA×CD3 bispecific antibody, the same class as etentamig ^[13].

The comparator AbbVie chose for itself. Janssen's teclistamab is built in as a comparator arm in AbbVie's own upcoming Phase 3 NCT07728188 — etentamig plus pomalidomide versus standard available therapy including a teclistamab arm, not yet open, planned start November 30, 2026 ^[5]. Janssen also runs teclistamab studies NCT04557098 and NCT03145181 ^[14][15]. Prognyx read: AbbVie has effectively volunteered a benchmark against the category's established bispecific.

Broader BCMA field, sequencing-exposed. GSK's belantamab mafodotin antibody-drug conjugate is in Phase 3 development, including NCT04484623 ^[19]; Kite/Gilead's anitocabtagene autoleucel CAR-T is in a Phase 3 versus standard of care, NCT06413498 ^[18]; Regeneron's linvoseltamab is in a Phase 3 against daratumumab in high-risk smoldering disease, NCT07393282 ^[17]; AstraZeneca's dual BCMA/CD19 CAR-T AZD0120 is in Phase 3, NCT07391657 ^[20]; and J&J's cilta-cel appears in NCT04133636 ^[16]. The registry states what each sponsor is testing, never how well it works ^{[16][17][18][19][20]}.

What to watch — with dates

• NCT07728188 (etentamig plus pomalidomide vs standard available therapy including a teclistamab arm): planned start November 30, 2026; not yet open ^[5].
• NCT07420959 (etentamig/ABBV-383 in relapsed/refractory Waldenström macroglobulinemia, sponsored by Mayo Clinic): planned start October 25, 2026 ^[9].
• NCT06158841 registered primary completion: December 2027 ^[4].
• Regulatory filing. No pathway — Priority Review, an accelerated approval route, a PDUFA date — is named anywhere in the dossier, and AbbVie's filing plans for etentamig are not established in the sources reviewed. Prognyx cannot convert a pathway it does not have into a decision window; the honest read is that filing timing is unknown.

The now-what

1. Re-baseline. Any holder of a BCMA×CD3 bispecific asset should re-baseline its comparative case against a monotherapy that just posted a reported 60% reduction in progression-or-death risk ^[1]; the bar a competing dataset must clear in relapsed/refractory myeloma moved this week.
2. Wait for NCT07728188 before committing to a teclistamab-combination position. AbbVie's own design pits etentamig against a teclistamab arm ^[5]; that trial, not today's press line, will decide whether the head-to-head claim holds.
3. Diligence the community-setting angle, but discount it until primary. Citeline trade coverage tied to the readout describes etentamig as suited to community use with monthly dosing and low toxicity — a positioning claim from a single secondary report, unconfirmed in the primary sources reviewed ^[22].

What Prognyx could not verify

Four gaps govern this briefing and none is closed by public sources reviewed: the CERVINO-to-NCT link (inferred, not stated by AbbVie); the exact response rate, PFS hazard ratio and p-values behind the 60% figure; AbbVie's regulatory-filing timeline; and any head-to-head efficacy, revenue or market-share data comparing etentamig to teclistamab or elranatamab — the competitive tie rests on teclistamab being a named comparator arm in AbbVie's own trial ^[5] and on elranatamab sharing the mechanism ^[13], nothing more.

Verdict. Threat level moderate-to-high for BCMA×CD3 bispecific holders; the window to position is before AbbVie files (timeline undisclosed) and before NCT07728188 opens around November 30, 2026 ^[5].